Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks-- and the track records of the firms behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 135,000 members, many of whom demonstrate better investing insight than published analysts do.
More top-performing CAPS members are feeling bullish about Abbott Laboratories
Abbott has a diverse portfolio of drugs and products, and many CAPS members see its dividend as a safe bet, thanks to its conservative payout. While some longtime dividend payers like General Electric
The company also sees many solid opportunities ahead, including a new drug combining its TriLipix with AstraZeneca's
On the legal front, Abbott recently won one federal appeals decision concerning its HIV medicine Norvir. If the company has its way on another appeal, it'll also reduce or eliminate the $1.67 billion in damages a jury recently granted to Johnson & Johnson
The Motley Fool Inside Value team looks for oversold stocks that are selling at bargain prices well below their intrinsic value. To see the full list of companies recommended today, take a free 30-day trial.
After years of practice, Fool contributor Dave Mock upgraded his chess ability to "barely competitive." He owns shares of Pfizer and Johnson & Johnson. Pfizer is an Inside Value recommendation. Johnson & Johnson is an Income Investor pick. The Fool's disclosure policy is currently working on its suntan in anticipation of next year's "America's top disclosure policy" competition.